A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)
Latest Information Update: 25 Jun 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 18 Jun 2025 Planned End Date changed from 2 Dec 2027 to 1 Feb 2028.
- 18 Jun 2025 Planned primary completion date changed from 9 Dec 2025 to 11 Nov 2025.
- 18 Jun 2025 Status changed from recruiting to active, no longer recruiting.